United Therapeutics Corporation (UTHR)
- Previous Close
234.47 - Open
233.61 - Bid 237.00 x 100
- Ask 240.27 x 100
- Day's Range
233.61 - 240.12 - 52 Week Range
204.44 - 261.54 - Volume
113,954 - Avg. Volume
459,004 - Market Cap (intraday)
11.286B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
12.11 - EPS (TTM)
19.80 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
292.25
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
www.unither.comRecent News: UTHR
Performance Overview: UTHR
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UTHR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UTHR
Valuation Measures
Market Cap
11.03B
Enterprise Value
8.73B
Trailing P/E
11.83
Forward P/E
10.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.00
Price/Book (mrq)
1.84
Enterprise Value/Revenue
3.75
Enterprise Value/EBITDA
6.30
Financial Highlights
Profitability and Income Statement
Profit Margin
42.31%
Return on Assets (ttm)
11.22%
Return on Equity (ttm)
18.27%
Revenue (ttm)
2.33B
Net Income Avi to Common (ttm)
984.8M
Diluted EPS (ttm)
19.80
Balance Sheet and Cash Flow
Total Cash (mrq)
2.99B
Total Debt/Equity (mrq)
12.24%
Levered Free Cash Flow (ttm)
607.29M
Research Analysis: UTHR
Company Insights: UTHR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: UTHR
Analyst Report: United Therapeutics Corp
United Therapeutics is a biotechnology company focused on the development and commercialization of therapeutic products for patients with cardiovascular conditions, cancer and infectious diseases. It has five approved products on the market and a strong new product pipeline. The company has roughly 1,168 employees and is a component of the S&P 400.
RatingPrice TargetMarket Digest: BJ, LH, MCD, MDU, ES, UTHR
Monday Tee Up: A Short but Busy Week
Analyst Report: United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
RatingPrice TargetAnalyst Report: United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
RatingPrice Target